BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Qaqish I, Schlam IM, Chakkera HA, Fonseca R, Adamski J. Carfilzomib: A cause of drug associated thrombotic microangiopathy. Transfusion and Apheresis Science 2016;54:401-4. [DOI: 10.1016/j.transci.2016.03.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Moliz C, Gutiérrez E, Cavero T, Redondo B, Praga M. Eculizumab as a treatment for atypical hemolytic uremic syndrome secondary to carfilzomib. Nefrología (English Edition) 2019;39:86-8. [DOI: 10.1016/j.nefroe.2018.02.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Moliz C, Gutiérrez E, Cavero T, Redondo B, Praga M. Síndrome hemolítico urémico atípico secundario al uso de carfilzomib tratado con eculizumab. Nefrología 2019;39:86-8. [DOI: 10.1016/j.nefro.2018.02.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
3 Yui JC, Van Keer J, Weiss BM, Waxman AJ, Palmer MB, D'agati VD, Kastritis E, Dimopoulos MA, Vij R, Bansal D, Dingli D, Nasr SH, Leung N. Proteasome inhibitor associated thrombotic microangiopathy: Proteasome inhibitor associated TMA. Am J Hematol 2016;91:E348-52. [DOI: 10.1002/ajh.24447] [Cited by in Crossref: 62] [Cited by in F6Publishing: 50] [Article Influence: 10.3] [Reference Citation Analysis]
4 Freyer CW, Bange EM, Skuli S, Hsu M, Lin J, Cuker A, Cohen AD, Garfall A. Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome in a Patient With Heterozygous CFHR3/CFHR1 Deletion Treated With Eculizumab. Clin Lymphoma Myeloma Leuk 2021:S2152-2650(21)00248-2. [PMID: 34366267 DOI: 10.1016/j.clml.2021.06.019] [Reference Citation Analysis]
5 Kozlowski P, Kameran Behnam K, Uggla B, Åström M. Carfilzomib-induced hemolysis is noticeably common but rarely shows features of thrombotic microangiopathy: A retrospective study. Eur J Haematol 2020;104:588-93. [PMID: 32115785 DOI: 10.1111/ejh.13401] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Sapet M, Fouillet L, Daguenet E, Laurent B, Guyotat D, Le Jeune C. [Proteinuria in multiple myeloma: Be careful to iatrogeny]. Bull Cancer 2020;107:519-20. [PMID: 32178835 DOI: 10.1016/j.bulcan.2020.01.014] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Camilleri M, Cuadrado M, Phillips E, Wilson W, Jenner R, Pang G, Kamora S, Streetly M, Popat R, Bygrave C, Owen R, Cavenagh J, Chapman M, Sive J, Eccersley L, Sheaff M, Benjamin R, Ramasamy K, Cook G, Virchis A, Chavda SJ, Clifton-Hadley L, Scully MA, Yong K. Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study. Br J Haematol 2021;193:750-60. [PMID: 33650100 DOI: 10.1111/bjh.17377] [Reference Citation Analysis]
8 Jeyaraman P, Borah P, Singh A, Chhabra GD, Khullar D, Dayal N, Naithani R. Thrombotic microangiopathy after carfilzomib in a very young myeloma patient. Blood Cells Mol Dis 2020;81:102400. [PMID: 31887694 DOI: 10.1016/j.bcmd.2019.102400] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
9 Lefebvre J, Glezerman IG. Kidney Toxicities Associated With Novel Cancer Therapies. Adv Chronic Kidney Dis 2017;24:233-40. [PMID: 28778363 DOI: 10.1053/j.ackd.2017.05.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
10 Haddadin M, Al-Sadawi M, Madanat S, Tam E, Taiwo E, Luhrs C, Mcfarlane SI. Late Presentation of Carfilzomib Associated Thrombotic Microangiopathy. Am J Med Case Rep 2019;7:240-3. [PMID: 31457071 DOI: 10.12691/ajmcr-7-10-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
11 Masias C, Vasu S, Cataland SR. None of the above: thrombotic microangiopathy beyond TTP and HUS. Blood 2017;129:2857-63. [PMID: 28416509 DOI: 10.1182/blood-2016-11-743104] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 9.0] [Reference Citation Analysis]
12 Darwin A, Malpica L, Dhanoa J, Hashmi H. Carfilzomib-induced atypical haemolytic uraemic syndrome: a diagnostic challenge and therapeutic success. BMJ Case Rep 2021;14:e239091. [PMID: 33637496 DOI: 10.1136/bcr-2020-239091] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Jindal N, Jandial A, Jain A, Lad D, Prakash G, Khadwal A, Nada R, Sethi J, Ahluwalia J, Malhotra P. Carfilzomib-induced thrombotic microangiopathy: A case based review. Hematol Oncol Stem Cell Ther 2020:S1658-3876(20)30118-7. [PMID: 32735793 DOI: 10.1016/j.hemonc.2020.07.001] [Reference Citation Analysis]
14 Monteith BE, Venner CP, Reece DE, Kew AK, Lalancette M, Garland JS, Shepherd LE, Pater JL, Hay AE. Drug-induced Thrombotic Microangiopathy with Concurrent Proteasome Inhibitor Use in the Treatment of Multiple Myeloma: A Case Series and Review of the Literature. Clinical Lymphoma Myeloma and Leukemia 2020;20:e791-800. [DOI: 10.1016/j.clml.2020.04.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
15 Paner A, Okwuosa TM, Richardson KJ, Libby EN. Triplet therapies - the new standard of care for multiple myeloma: how to manage common toxicities. Expert Rev Hematol 2018;11:957-73. [PMID: 30339769 DOI: 10.1080/17474086.2018.1538777] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
16 Blasco M, Martínez-Roca A, Rodríguez-Lobato LG, Garcia-Herrera A, Rosiñol L, Castro P, Fernández S, Quintana LF, Cibeira MT, Bladé J, Fernández de Larrea C, Tovar N, Jimenez R, Poch E, Guillen E, Campistol JM, Carreras E, Diaz-Ricart M, Palomo M. Complement as the enabler of carfilzomib-induced thrombotic microangiopathy. Br J Haematol 2021;193:181-7. [PMID: 32469083 DOI: 10.1111/bjh.16796] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
17 Efentakis P, Doerschmann H, Witzler C, Siemer S, Nikolaou PE, Kastritis E, Stauber R, Dimopoulos MA, Wenzel P, Andreadou I, Terpos E. Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib. Int J Mol Sci 2020;21:E5185. [PMID: 32707866 DOI: 10.3390/ijms21155185] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Wanchoo R, Abudayyeh A, Doshi M, Edeani A, Glezerman IG, Monga D, Rosner M, Jhaveri KD. Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma. Clin J Am Soc Nephrol 2017;12:176-89. [PMID: 27654928 DOI: 10.2215/CJN.06100616] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
19 Gavazzoni M, Lombardi CM, Vizzardi E, Gorga E, Sciatti E, Rossi L, Belotti A, Rossi G, Metra M, Raddino R. Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: Early in vivo cardiovascular effects. European Journal of Pharmacology 2018;838:85-90. [DOI: 10.1016/j.ejphar.2018.09.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
20 Cassol CA, Williams MPA, Caza TN, Rodriguez S. Renal and pulmonary thrombotic microangiopathy triggered by proteasome-inhibitor therapy in patient with smoldering myeloma: A renal biopsy and autopsy case report. Medicine (Baltimore) 2019;98:e17148. [PMID: 31574818 DOI: 10.1097/MD.0000000000017148] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Brocklebank V, Kavanagh D. Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clin Kidney J 2017;10:600-24. [PMID: 28980670 DOI: 10.1093/ckj/sfx081] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]